#USA #San Francisco #Nektar Therapeutics #NKTR-358 #autoimmune disorders

Nektar Therapeutics' Q1 2025 Financial Results

On May 8, 2025, Nektar Therapeutics (Nasdaq: NKTR) announced its financial results for the first quarter ended March 31, 2025. The San Francisco-based biotechnology firm reported a significant shift in revenue and ongoing development in their product pipeline, particularly focusing on innovative therapies for autoimmune and chronic inflammatory diseases.

Financial Overview

Nektar’s cash and marketable securities totaled $220.7 million at the end of March, a decrease from $269.1 million as of December 31, 2024. This financial backing is expected to sustain strategic operations and development projects up to the fourth quarter of 2026.

The company recorded revenue of $10.5 million in the first quarter, down from $21.6 million the previous year. This decline was attributed mainly to the cessation of product sales following the divestment of the Huntsville manufacturing facility in December 2024, which altered their operational income structure.

Operating costs also reflected improvements, totaling $55.0 million compared to $57.1 million in Q1 2024. Reduced costs were a direct result of removing the cost of goods sold after selling the manufacturing facility, although an uptick in research and development (R&D) expenses was noted, reaching $30.5 million.

Nektar’s net loss for the quarter stood at $50.9 million, translating to a loss of $0.24 per share. This was a notable increase from a net loss of $36.8 million, or $0.19 per share, reported in Q1 2024. Adjusted for a $4.5 million non-cash loss associated with their equity investment in Gannet BioChem, the non-GAAP net loss for the quarter amounted to $46.4 million.

Development Highlights

Nektar's CEO, Howard W. Robin, emphasized ongoing clinical trials as key components of their strategic direction. Notably, the company expects to disclose topline data for the Phase 2 study of rezpegaldesleukin in treating atopic dermatitis in June 2025, followed by data for alopecia areata in December. This first-in-class T regulatory cell biologic is seen as a potential breakthrough for millions suffering from chronic autoimmune disorders.

Furthermore, Nektar anticipates submitting an Investigational New Drug (IND) application for NKTR-0165, their innovative antibody targeting the TNFR2 receptor, by the year's end. This drug has promising indications for multiple sclerosis, ulcerative colitis, and vitiligo.

Another highlight from their development pipeline includes NKTR-0166, a bispecific antibody combining a TNFR2 epitope with a well-validated antibody target, which is progressing into preclinical studies.

Recent achievements include the European Hematological Association selecting an abstract related to Nektar's research for oral presentation at their upcoming Congress in June 2025. Additionally, they recently completed target enrollment for a Phase 2b trial of rezpegaldesleukin aimed at severe alopecia areata and a clinical agreement with TrialNet to study the drug in patients with new-onset type 1 diabetes.

The FDA also gave Fast Track designation to rezpegaldesleukin for patients aged 12 and older suffering from moderate-to-severe atopic dermatitis, an encouraging development considering the regulatory landscape's complexities.

Conclusion

In summary, while Nektar Therapeutics' Q1 performance reveals some financial strain, the company remains optimistic about its future. With ongoing trials and significant pipeline developments, Nektar is poised to play a critical role in treating various serious diseases. The upcoming conference call will shed further light on these developments and broader company strategies.